Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

According to Benzinga Pro, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.87%, ...

BofA raised the firm’s price target on Alnylam (ALNY) to $328 from $325 and keeps a Buy rating on the shares. The firm updated models in ...

Alnylam Pharmaceuticals ALNY -3.78% Get Free Report has outperformed the market over the past 15 years by 8.52% on an ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take ...

Morgan Stanley lowered the firm’s price target on Alnylam (ALNY) to $268 from $284 and keeps an Equal Weight rating on the shares. The firm is ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam Pharmaceuticals in a ...